Representatives Rich McCormick (R-GA07) and Rosa DeLauro (D-CT03) have introduced the bipartisan Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act.
Senators Rick Scott (R-FL) and Kirsten Gillibrand (D-NY) are also leading the effort by bringing the bill to the Senate.
Rep. McCormick expressed great pride in cosponsoring this bill and highlighted the need for transparency on this issue. According to him, Americans deserve to know where their prescription drugs are manufactured and how that is done.
"I'm proud to be the House co-lead of the CLEAR LABELS Act. This bipartisan and bicameral bill will bring transparency to consumers, pharmacists, and providers about the country of origin of pharmaceuticals and APIs while empowering stakeholders with knowledge of where their medications come from,” said Rep. McCormick.
He continued, “Americans deserve to know where their prescription drugs, or the APIs used to make them, are manufactured. I'm proud to work alongside Representative DeLauro and Senators Scott and Gillibrand to pass this legislation.”
The Bill and its Context
Many prescription drugs, and the active pharmaceutical ingredients (APIs) they rely on, are manufactured overseas, including China.
Current federal labeling rules do not require disclosure of where these ingredients or finished drugs are made, leaving patients and providers without key information.
The CLEAR LABELS Act would change that. It requires prescription drug labels to clearly list the original manufacturers of both the drugs and their APIs, giving Americans the transparency they deserve and ensuring stronger accountability in the pharmaceutical supply chain.
On determining the methods of disclosure, the bill allows for digital and physical formats. For example, the necessary information can be provided via a link, barcode, QR code, package insert, or paper copy.
The bill also provides key definitions and timeline requirements. The original manufacturer is defined as the last establishment to adjust the product before it enters the market. The requirements will apply to drugs manufactured or distributed after the effective date.
When you pick up a prescription, you should know where it was made. That's just common sense.
I'm proud to co-lead the bicameral, bipartisan CLEAR LABELS Act alongside @SenRickScott, @rosadelauro, & @SenGillibrand to require country-of-origin labeling for prescription drugs and… pic.twitter.com/BBnd8RstbN
— Congressman Rich McCormick, MBA MD (@RepMcCormick) April 14, 2026
